EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

The Role of Pretherapy Quantitative Imaging and Dosimetry in Radioiodine Therapy for Advanced Thyroid Cancer

Jan Taprogge, Carla Abreu, Siraj Yusuf, Gemma Ainsworth, Rachel H Phillip, Jonathan I Gear, Rebecca Gregory, Francesca Leek, Iain Murray, Amy B Coulson, Sarah R Brown, Yong Du und 3 weitere

Journal of Nuclear Medicine · 2023-07 · 64 (7) · 1125-1130

DOI: 10.2967/jnumed.122.264913 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 28.04.2023. Verfasst von Jan Taprogge und 14 weiteren Autor:innen. Beteiligte Einrichtung: Joint Department of Physics, Royal Marsden NHSFT, Sutton, United Kingdom; jan.taprogge@icr.ac.uk. Hauptthemen laut MEDLINE: Thyroid Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radioactive iodine is well established as a successful treatment for differentiated thyroid cancer (DTC), although around 15% of patients have local recurrence or develop distant metastases and may become refractory to radioactive iodine (RAI). A personalized approach to treatment, based on the absorbed radiation doses delivered and using treatments to enhance RAI uptake, has not yet been developed.

Methods

We performed a multicenter clinical trial to investigate the role of selumetinib, which modulates the expression of the sodium iodide symporter, and hence iodine uptake, in the treatment of RAI-refractory DTC. The iodine uptake before and after selumetinib was quantified to assess the effect of selumetinib. The range of absorbed doses delivered to metastatic disease was calculated from pre- and posttherapy imaging, and the predictive accuracy of a theranostic approach to enable personalized treatment planning was investigated.

Results

Significant inter- and intrapatient variability was observed with respect to the uptake of RAI and the effect of selumetinib. The absorbed doses delivered to metastatic lesions ranged from less than 1 Gy to 1,170 Gy. A strong positive correlation was found between the absorbed doses predicted from pretherapy imaging and those measured after therapy (r = 0.93, P < 0.001).

Conclusion

The variation in outcomes from RAI therapy of DTC may be explained, among other factors, by the range of absorbed doses delivered. The ability to assess the effect of treatments that modulate RAI uptake, and to estimate the absorbed doses at therapy, introduces the potential for patient stratification using a theranostic approach. Patient-specific absorbed dose planning might be the key to more successful treatment of advanced DTC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsHumansIodine RadioisotopesRadiometryDiagnostic Imaging

Stichwörter der Autor:innen

advanced thyroid cancerdosimetryradioiodinetheragnostics

Substanzen

Iodine Radioisotopes

Autor:innen und Institutionen

  • Joint Department of Physics, Royal Marsden NHSFT, Sutton, United Kingdom; jan.taprogge@icr.ac.uk.
  • Institute of Cancer Research, London, United Kingdom.
  • Joint Department of Physics, Royal Marsden NHSFT, Sutton, United Kingdom.
  • Department of Nuclear Medicine and PET/CT, Royal Marsden NHSFT, Sutton, United Kingdom.
  • Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.
  • Thyroid Unit, Royal Marsden NHSFT, Sutton, United Kingdom; and.

Förderung

  • Cancer Research UK

Zitieren

APA

Taprogge, J., Abreu, C., Yusuf, S., Ainsworth, G., Phillip, R. H., Gear, J. I., Gregory, R., Leek, F., Murray, I., Coulson, A. B., Brown, S. R., Du, Y., Newbold, K., Wadsley, J., & Flux, G. D. (2023). The Role of Pretherapy Quantitative Imaging and Dosimetry in Radioiodine Therapy for Advanced Thyroid Cancer. Journal of Nuclear Medicine, 64(7), 1125-1130. https://doi.org/10.2967/jnumed.122.264913

Vancouver

Taprogge J, Abreu C, Yusuf S, Ainsworth G, Phillip RH, Gear JI, et al. The Role of Pretherapy Quantitative Imaging and Dosimetry in Radioiodine Therapy for Advanced Thyroid Cancer. Journal of Nuclear Medicine. 2023;64(7):1125-1130. doi:10.2967/jnumed.122.264913

BibTeX
@article{Taprogge2023,
  author = {Taprogge, Jan and Abreu, Carla and Yusuf, Siraj and Ainsworth, Gemma and Phillip, Rachel H and Gear, Jonathan I and Gregory, Rebecca and Leek, Francesca and Murray, Iain and Coulson, Amy B and Brown, Sarah R and Du, Yong and Newbold, Kate and Wadsley, Jonathan and Flux, Glenn D},
  title = {The Role of Pretherapy Quantitative Imaging and Dosimetry in Radioiodine Therapy for Advanced Thyroid Cancer},
  journal = {Journal of Nuclear Medicine},
  year = {2023},
  volume = {64},
  number = {7},
  pages = {1125--1130},
  doi = {10.2967/jnumed.122.264913}
}
Kostenlos starten →